Skip to main content
← All trials
Primary Membranous NephropathyDrugPhase 2, Phase 3

What this study is

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

What's being tested

  • Povetacicept

    Intervention · DRUG

    Solution for Subcutaneous Injection.

  • Tacrolimus

    Intervention · DRUG

    Capsules for Oral Administration.

Study details

Official title
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Sponsor
Vertex Pharmaceuticals Incorporated
Conditions
Primary Membranous Nephropathy
Enrolling
176 people
Starts
2025-09-30
Est. completion
2028-12-29
Design
Quadruple-blind, randomized, sequential groups, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗